Brief: Matinas BioPharma Announces Positive Opinion By The European Medicines Agency On Orphan Drug Designation For MAT2203 For The Treatment Of Cryptococcosis
25/07/2022 11:35
July 25 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA ANNOUNCES POSITIVE OPINION BY THE
EUROPEAN
MEDICINES AGENCY ON ORPHAN DRUG DESIGNATION FOR MAT2203 FOR THE
TREATMENT OF CRYPTOCOCCOSIS
* MATINAS BIOPHARMA HOLDINGS INC - IS CURRENTLY PREPARING TO
EVALUATE MAT2203 IN A PIVOTAL PHASE 3 TRIAL IN PATIENTS WITH
CRYPTOCOCCAL MENINGITIS
Source text for Eikon: ID:nGNX2tMZKp
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing